KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Retained Earnings (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Retained Earnings for 15 consecutive years, with -$44000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 100.01% to -$44000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$44000.0, a 100.01% decrease, with the full-year FY2025 number at -$44000.0, down 100.01% from a year prior.
  • Retained Earnings was -$44000.0 for Q4 2025 at Supernus Pharmaceuticals, down from $522.0 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $556.4 million in Q4 2024 to a low of -$3.2 million in Q4 2022.
  • A 5-year average of $256.5 million and a median of $344.1 million in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: surged 200215.66% in 2021, then plummeted 308.58% in 2022.
  • Supernus Pharmaceuticals' Retained Earnings stood at $1.5 million in 2021, then crashed by 308.58% to -$3.2 million in 2022, then surged by 81.53% to -$593000.0 in 2023, then soared by 93932.38% to $556.4 million in 2024, then crashed by 100.01% to -$44000.0 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Retained Earnings are -$44000.0 (Q4 2025), $522.0 million (Q3 2025), and -$200000.0 (Q2 2025).